Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance Xeris (Nasdaq: XERS) reported record Q4 revenue of $85.8M and full‑year 2025 revenue of $291.8M, driven by Recorlev, Gvoke and Keveyis growth. The company gave 2026 guidance of $375M–$390M, expects higher R&D and SG&A spend to support XP‑8121 Phase 3 and Recorlev expansion, and reported Adjusted EBITDA improvement.

#XERS Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

www.stocktitan.net/news/XERS/xeris-biopharm...

We acknowledge that this “war” is a measuring contest between #DirtyDonald & #BadBoyBB but as #Xers, Blue Star & Lebanese fams, we’re not at all upset by this. This administration has NO respect for anything but Iran has killed SO MANY people in the region…
Know why you’re protesting…

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit {"summary":"","positive":[],"negative":[],"faq":[]}

#XERS Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

www.stocktitan.net/news/XERS/xeris-biopharm...

#XERS Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

www.stocktitan.net/news/XERS/xeris-announce...

#XERS Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

www.stocktitan.net/news/XERS/xeris-biopharm...

Patent Protection Until 2040: Xeris Adds Critical IP Shield for Rare Disease Drug Recorlev in FDA Orange Book Xeris Biopharma's Recorlev gains new patent protection for drug-drug interaction methods. Fourth Orange Book listing extends exclusivity for Cushing's syndrome treatment through 2040.

#XERS Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

www.stocktitan.net/news/XERS/xeris-announce...

Dr. Manhattan from Watchmen sits naked atop a rock on the face of the moon, its lifeless, cratered landscape spreading out, glowing pink in the light. The cold depths of space, star-strewn, lie beyond. Like this increasingly cliche meme or the inevitable shaming of the newest generation, time has no meaning to him.

It's 1965, #boomers are lazy and entitled, unlike prior #generations

It's 1985, #xers are lazy and entitled, unlike prior gens

It's 2005, #millenials are lazy and entitled, unlike prior gens

It's 2025, #zoomers are lazy and entitled, unlike prior gens

Xeris Unveils Ambitious $3 Billion Revenue Plan: Key Pipeline Drug Could Transform Hypothyroidism Treatment Xeris projects $750M revenue by 2030 and reveals blockbuster potential for hypothyroidism drug XP-8121. Get exclusive details from their first Analyst Day presentation.

#XERS Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

www.stocktitan.net/news/XERS/xeris-unveils-...

Xeris Biopharma Reports Record First Quarter 2025 Financial Results Xeris Biopharma (XERS) reported strong Q1 2025 financial results with total revenue increasing 48% YoY to $60.1 million. The company's flagship product Recorlev saw exceptional growth with revenue up 141% YoY to $25.5 million, driven by a 124% increase in patient numbers. Gvoke revenue grew 26% to $20.8 million, while Keveyis revenue declined 13% to $11.4 million. The company tightened its full-year 2025 revenue guidance to $260-275 million from the previous $255-275 million range. Net loss for Q1 was $9.2 million ($0.06 per share), with Adjusted EBITDA positive at $4.4 million, an $8.4 million improvement YoY. The company will host an Analyst & Investor Day on June 3rd, 2025, in New York City.

#XERS Xeris Biopharma Reports Record First Quarter 2025 Financial Results

www.stocktitan.net/news/XERS/xeris-biopharm...

Breakthrough FDA Approval: Xeris' Novel Glucagon Solution Transforms Radiologic Diagnostics Xeris secures FDA approval for Gvoke VialDx, pioneering ready-to-dilute glucagon solution, targeting 20M annual GI procedures through American Regent partnership.

#XERS Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

www.stocktitan.net/news/XERS/xeris-announce...

Can Xeris Biopharma's Record-Breaking Quarter Signal a New Growth Phase? Q4 revenue surges 35% with strong performance across key products. Company demonstrates financial momentum with positive cash flow and ambitious 2025 outlook.

#XERS Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

www.stocktitan.net/news/XERS/xeris-biopharm...

Micro-retirement: has gen Z found a brilliant fix for burnout? Why wait until you’re in your 60s or 70s to enjoy yourself? Some young people are opting for short periods off throughout their working lives

Why don't they just take up drinking? It worked for #Milennials and #Xers.

#GenZ

#Xers we really have work to do…yikes I thought we were better.

Xeris Biopharma Exceeds 2024 Guidance with $203M Revenue, Posts Record Q4 Growth Xeris reports strong Q4 performance with 35% revenue growth, achieves first cash-flow positive quarter, and maintains robust market position with Gvoke reaching 35% share.

#XERS Xeris Expects to Exceed Full-Year 2024 Financial Guidance

www.stocktitan.net/news/XERS/xeris-expects-...

#XERS Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/XERS/xeris-to-parti...